Share Email Print

Proceedings Paper

The Ad5 [E1-, E2b-]-based vector: a new and versatile gene delivery platform
Author(s): Frank R. Jones; Elizabeth S. Gabitzsch; Joseph P. Balint
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Based upon advances in gene sequencing and construction, it is now possible to identify specific genes or sequences thereof for gene delivery applications. Recombinant adenovirus serotype-5 (Ad5) viral vectors have been utilized in the settings of gene therapy, vaccination, and immunotherapy but have encountered clinical challenges because they are recognized as foreign entities to the host. This recognition leads to an immunologic clearance of the vector that contains the inserted gene of interest and prevents effective immunization(s). We have reported on a new Ad5-based viral vector technology that can be utilized as an immunization modality to induce immune responses even in the presence of Ad5 vector immunity. We have reported successful immunization and immunotherapy results to infectious diseases and cancers. This improved recombinant viral platform (Ad5 [E1-, E2b-]) can now be utilized in the development of multiple vaccines and immunotherapies.

Paper Details

Date Published: 13 May 2015
PDF: 11 pages
Proc. SPIE 9490, Advances in Global Health through Sensing Technologies 2015, 94900L (13 May 2015); doi: 10.1117/12.2183244
Show Author Affiliations
Frank R. Jones, Etubics Corp. (United States)
Elizabeth S. Gabitzsch, Etubics Corp. (United States)
Joseph P. Balint, Etubics Corp. (United States)

Published in SPIE Proceedings Vol. 9490:
Advances in Global Health through Sensing Technologies 2015
Šárka O. Southern; Mark A. Mentzer; Virginia E. Wotring, Editor(s)

© SPIE. Terms of Use
Back to Top